- Conditions
- COVID, COVID-19, Corona Virus Infection, SARS-CoV-2
- Interventions
- Tear Collection
- Diagnostic Test
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 158
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Covid19, SARS (Severe Acute Respiratory Syndrome), Corona Virus Infection
- Interventions
- Lucira COVID-19 All-In-One test kit
- Device
- Lead sponsor
- Lucira Health Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Los Gatos, California
- Conditions
- Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma, Recurrent Skin Clear Cell Squamous Cell Carcinoma, Recurrent Skin Lymphoepithelial Carcinoma, Recurrent Skin Spindle Cell Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Resectable Eyelid Squamous Cell Carcinoma, Resectable Skin Acantholytic Squamous Cell Carcinoma, Resectable Skin Clear Cell Squamous Cell Carcinoma, Resectable Skin Lymphoepithelial Carcinoma, Resectable Skin Spindle Cell Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Skin Acantholytic Squamous Cell Carcinoma, Skin Clear Cell Squamous Cell Carcinoma, Skin Lymphoepithelial Carcinoma, Skin Spindle Cell Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Cemiplimab, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Surgical Procedure
- Procedure · Biological · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 196
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 147 more
- Conditions
- Breast Cancer
- Interventions
- letrozole, panobinostat, RNA analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay, immunohistochemistry staining method, laboratory biomarker analysis
- Drug · Genetic · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 172
- States / cities
- Scottsdale, Arizona • Martinez, California • Mountain View, California + 119 more
- Conditions
- COVID-19
- Interventions
- ELISA, RT-PCR
- Diagnostic Test
- Lead sponsor
- Igenomix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Pleasant Grove, Utah
- Conditions
- COVID-19, Influenza A, Influenza Type B
- Interventions
- COVID-19/ Flu A&B Rapid Panel
- Device
- Lead sponsor
- Abbott Rapid Diagnostics Jena GmbH
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,472 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Easley, South Carolina
- Conditions
- Leukemia
- Interventions
- panobinostat, gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis
- Drug · Genetic · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- Duarte, California • Pasadena, California
- Conditions
- Breast Cancer Female
- Interventions
- Letrozole
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
- Interventions
- laboratory biomarker analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 17 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Corona Virus Infection, Pregnancy Related
- Interventions
- COVID-19 positive via testing
- Other
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 650 participants
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Falls Church, Virginia
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- panobinostat, fluorouracil, leucovorin calcium, biopsy, reverse transcriptase-polymerase chain reaction, western blotting, laboratory biomarker analysis, gene expression analysis, RNA analysis, polymorphism analysis
- Drug · Procedure · Genetic + 1 more
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Leukemia
- Interventions
- reverse transcriptase-polymerase chain reaction
- Genetic
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 9,769 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2006
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more
- Conditions
- Lassa Fever
- Interventions
- ARN-75039 high, Intravenous ribavirin, ARN-75039 low
- Drug
- Lead sponsor
- Arisan Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Carlsbad, California
- Conditions
- Head and Neck Cancer
- Interventions
- gene expression analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunohistochemistry staining method, needle biopsy
- Genetic · Other · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- HIV Infections
- Interventions
- Atazanavir, Stavudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2006
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Atlanta, Georgia • Chicago, Illinois
- Conditions
- Coronary Artery Disease
- Interventions
- biomarker samples
- Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Neuroblastoma
- Interventions
- adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH, oral β-glucan
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies, Childhood Acute Myelomonocytic Leukemia (M4)
- Interventions
- laboratory biomarker analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Monrovia, California
- Conditions
- Covid19
- Interventions
- T-Detect COVID test
- Device
- Lead sponsor
- Adaptive Biotechnologies
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 203 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Fullerton, California • Los Angeles, California + 12 more
- Conditions
- Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bortezomib, pemetrexed disodium, gene expression analysis, mutation analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, immunohistochemistry staining method
- Drug · Genetic · Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Interventions
- oxaliplatin, pemetrexed disodium, questionnaire administration, laboratory biomarker analysis, reverse transcriptase-polymerase chain reaction, polymorphism analysis
- Drug · Other · Genetic
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Sarcoma
- Interventions
- DNA analysis, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis
- Genetic · Other
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- Not listed
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- COVID-19, Influenza A, Influenza B
- Interventions
- Panbio™
- Diagnostic Test
- Lead sponsor
- Abbott Rapid Dx
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Vienna, Virginia
- Conditions
- Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- celecoxib, recombinant interferon alfa-2b, polymerase chain reaction, laboratory biomarker analysis, reverse transcriptase-polymerase chain reaction, immunologic technique, immunohistochemistry staining method, flow cytometry
- Drug · Biological · Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio